Trial Profile
A Prospective, Randomized, Double-Blind, Placebo-Controlled Study of the Effectiveness and Safety of Risperidal CONSTA Augmentation in Adult Patients With Frequently-Relapsing Bipolar Disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 May 2010
Price :
$35
*
At a glance
- Drugs Risperidone (Primary)
- Indications Bipolar disorders; Bipolar I disorders
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Research & Development
- 01 Jan 2010 Results were reported in Bipolar Disorders.
- 03 Sep 2008 Results were presented at ECNP 2008.
- 17 Jul 2008 Results have been presented at the 26th Collegium Internationale Neuro Psychopharmacologicum Congress.